Baker IDI Heart and Diabetes Institute, Adelaide, South Australia, Australia.
Curr Opin Lipidol. 2011 Feb;22(1):1-5. doi: 10.1097/MOL.0b013e328340b8fd.
The use of bariatric surgery is increasing at an enormous rate in all countries but the indications for the operation on the basis of metabolic derangements are not clear as only one controlled randomized trial has been performed so far. Thus, it is not clear whether bariatric surgery should be performed on obese patients with long-standing type 2 diabetes or poorly controlled hypertension or hypertriglyceridemia. The mechanism for the immediate improvement in glucose tolerance after gastric bypass is not clear but is being actively investigated.
Gastric bypass appears to enhance glucagon-like peptide-1 production and suppress glucose-dependent insulinotropic polypeptide production. It appears that patients with type 2 diabetes and a greater BMI gain more benefit from the operation.
Bariatric surgery, particularly gastric bypass, has powerful and usually persistent effects on type 2 diabetes, dyslipidemia, and hypertension but randomized controlled trials with predefined metabolic entry criteria and planned comprehensive follow-up are required.
在所有国家,肥胖症手术的应用正在以惊人的速度增长,但由于迄今为止仅进行了一项对照随机试验,因此代谢紊乱手术指征尚不清楚。因此,目前尚不清楚肥胖症伴 2 型糖尿病、控制不佳的高血压或高三酰甘油血症患者是否应进行肥胖症手术。胃旁路术后血糖耐量即刻改善的机制尚不清楚,但正在积极研究中。
胃旁路似乎可增加胰高血糖素样肽-1 的产生并抑制葡萄糖依赖性胰岛素释放多肽的产生。似乎是体重指数较高的 2 型糖尿病患者从手术中获益更多。
减肥手术,特别是胃旁路术,对 2 型糖尿病、血脂异常和高血压有强大且通常持久的作用,但需要有明确代谢指标和全面随访计划的随机对照试验。